Publications by authors named "Fanghua Xun"
Hepatocellular carcinoma (HCC) has garnered significant attention from researchers due to its high recurrence rate and invasive characteristics. The design of drugs with dual-target combined effects represents a promising strategy in cancer treatment. Our observations suggest that ADAM17 and HDAC may inhibit the unfavorable prognostic signaling pathway Notch1 in HCC through distinct mechanisms, thereby suppressing tumor cell proliferation and metastasis.
View Article and Find Full Text PDFArticle Synopsis
- The study investigates the effectiveness and safety of various PI3K/AKT inhibitors in treating cancers, focusing on comparing their efficacy across different cancer types.
- An analysis of 34 studies with 6,710 patients revealed that these inhibitors are particularly effective for mutant cancers, although they often have poor safety profiles.
- Specifically, capivasertib was noted as effective for solid tumors like breast cancer, while idelalisib was effective for hematological cancers such as chronic lymphocytic leukemia.